Sign in

    Kaey Nakae • Chardan

    Kaey Nakae's questions to Silence Therapeutics PLC (SLN) leadership

    Kaey Nakae's questions to Silence Therapeutics PLC (SLN) leadership • FY 2024

    Question

    Kaey Nakae asked about the status of the drug candidates from the recently concluded Hansoh Pharma collaboration and whether Silence Therapeutics intends to continue their development.

    Answer

    President and CEO Craig Tooman confirmed strong interest in the programs, citing encouraging preclinical data. He explained that Silence now has full control to either develop the assets internally or seek new partnerships. CFO Rhonda Hellums clarified the financial impact, noting that the conclusion of the agreement triggered a one-time cumulative revenue recognition in 2024, with no further revenue expected from Hansoh.

    Ask Fintool Equity Research AI

    Kaey Nakae's questions to Arbutus Biopharma Corp (ABUS) leadership

    Kaey Nakae's questions to Arbutus Biopharma Corp (ABUS) leadership • Q3 2024

    Question

    Kaey Nakae from Chardan sought more clarity on the anticipated timing for the initiation of the Phase IIb clinical trial for imdusiran.

    Answer

    Interim President and CEO Mike McElhaugh responded that he could not provide a specific timeline for the Phase IIb trial at this point. He emphasized that the company is diligently working through the process, which includes reviewing all available and upcoming data and planning discussions with regulators to advance the program as quickly as possible.

    Ask Fintool Equity Research AI

    Kaey Nakae's questions to Arbutus Biopharma Corp (ABUS) leadership • Q2 2024

    Question

    Kaey Nakae pressed for more clarity on the timeline for initiating the next clinical trial, asking if a start in the first half of 2025 was a reasonable expectation, and sought confirmation that Arbutus has the resources to launch the trial independently.

    Answer

    Interim President and CEO Mike McElhaugh reiterated that the goal is to start the trial as quickly as possible but declined to provide a specific timeline, as it depends on pending data. He strongly affirmed that following the restructuring, the company has the financial resources and cash on hand to substantially fund and initiate the trial on its own.

    Ask Fintool Equity Research AI

    Kaey Nakae's questions to Arbutus Biopharma Corp (ABUS) leadership • Q1 2024

    Question

    Kaey Nakae asked if the receptor occupancy assay for AB-101 was custom-developed, whether the dose response met expectations, the dosing frequency in the multi-ascending dose study, and the expected timeline for advancing to Part 3 of the trial in HBV patients.

    Answer

    Chief Scientific Officer Dr. Michael Sofia confirmed the target occupancy assay was developed internally and that the clinical results are encouraging and align with preclinical models. Chief Medical Officer Dr. Karen Sims added that the multi-ascending dose portion involves a 7-day duration with flexible frequency and that progression to Part 3 is dependent on the data from Part 2, though the protocol is designed for a seamless transition.

    Ask Fintool Equity Research AI